X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GLAXOSMITHKLINE PHARMACEUTICALS LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

GLAXOSMITHKLINE PHARMACEUTICALS LTD.  (GLXO)


Here is the latest financial fact sheet of GSK Pharma. For more details, see the GSK Pharma quarterly results and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
gsk pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 2,576.7       No. of shares m 84.70
    Mkt Cap Rs m 218,242       % ch % -0.7
    Vol '000 1.4       % ch week % -3.6
    P/E X 66.1       % ch 1-mth % -6.5
    P/CF X 54.6       % ch 12-mth % -29.4
    EPS (TTM) Rs 39.0       52 week H/L Rs 3,805.9/2,570.0
(As on Apr 24, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Dec-11
12
Dec-12
12
Dec-13
15
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs2,4752,3383,0023,5503,850 
Low Rs1,8301,9162,0052,3522,966 
Sales per share (Unadj.) Rs285.1312.9302.6396.5332.3 
Earnings per share (Unadj.) Rs50.666.356.955.744.3 
Diluted earnings per shareRs50.666.356.955.744.3 
Cash flow per share (Unadj.) Rs53.068.459.258.747.2 
Dividends per share (Unadj.) Rs45.0050.0050.0062.5050.00 
Adj. dividends per shareRs45.0050.0050.0062.5050.00 
Dividend yield (eoy) %2.12.42.02.11.5 
Book value per share (Unadj.) Rs228.5236.9234.9215.9202.7 
Adj. book value per shareRs228.5236.9234.9215.9202.7 
Shares outstanding (eoy) m84.7084.7084.7084.7084.70 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x7.66.88.37.410.3 
Avg P/E ratio x42.532.144.053.076.9 
P/CF ratio (eoy) x40.631.142.350.372.2 
Price / Book Value ratio x9.49.010.713.716.8 
Dividend payout %88.975.487.9112.2112.9 
Avg Mkt Cap Rs m182,317180,157212,038249,933288,643 
No. of employees `0005.14.75.04.74.6 
Total wages/salary Rs m2,7842,9553,6214,9304,434 
Avg. sales/employee Rs Th4,776.35,632.25,090.87,211.76,104.5 
Avg. wages/employee Rs Th550.7627.9719.31,058.6961.6 
Avg. net profit/employee Rs Th847.71,194.0956.91,012.7813.7 
  INCOME DATA
Net Sales Rs m24,14426,50525,62733,58528,148 
Other income Rs m1,4561,7461,7701,9991,218 
Total revenues Rs m25,60028,25127,39735,58429,366 
Gross profit Rs m8,0248,2615,2826,2834,774 
Depreciation Rs m204178199254248 
Interest Rs m33000 
Profit before tax Rs m9,2739,8266,8538,0285,744 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-3,154-1,482262-51926 
Tax Rs m1,8342,7252,2982,7932,018 
Profit after tax Rs m4,2855,6194,8174,7163,752 
Gross profit margin %33.231.220.618.717.0 
Effective tax rate %19.827.733.534.835.1 
Net profit margin %17.721.218.814.013.3 
  BALANCE SHEET DATA
Current assets Rs m26,05126,46726,23925,87021,462 
Current liabilities Rs m8,5968,3648,88911,06510,536 
Net working cap to sales %72.368.367.744.138.8 
Current ratio x3.03.23.02.32.0 
Inventory Days Days5039494168 
Debtors Days Days1316141116 
Net fixed assets Rs m1,1531,3321,6202,3834,717 
Share capital Rs m847847847847847 
"Free" reserves Rs m18,49319,20419,03317,65316,308 
Net worth Rs m19,35720,06819,89718,29017,171 
Long term debt Rs m4641362616 
Total assets Rs m29,68130,01731,29532,36430,620 
Interest coverage x3,092.03,276.3NMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x0.80.90.81.00.9 
Return on assets %14.418.715.414.612.3 
Return on equity %22.128.024.225.821.9 
Return on capital %31.641.535.741.033.6 
Exports to sales %1.50.70.40.20 
Imports to sales %7.88.112.312.915.1 
Exports (fob) Rs m36519695634 
Imports (cif) Rs m1,8732,1523,1594,3344,237 
Fx inflow Rs m799715625699519 
Fx outflow Rs m3,6424,1415,3807,6808,320 
Net fx Rs m-2,843-3,426-4,755-6,981-7,801 
  CASH FLOW
From Operations Rs m 3,354 3,136 2,813 3,409 1,386 
From Investments Rs m 3,580 -1,097 1,890 1,776 5,010 
From Financial Activity Rs m -3,948 -4,406 -4,941 -4,970 -6,383 
Net Cashflow Rs m 2,986 -2,367 -239 215 12 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for glaxosmithkline pharmaceuticals ltd.

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 50.7%
Indian inst/Mut Fund : 10.2%
FIIs : 23.8%
ADR/GDR : 0.0%
Free float : 15.4%
Shareholders : 102,036
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Dr. Annie Besant Road, Worli, Mumbai - 400 030
    E-MAIL: ajay.a.nadkarni@gsk.com     WEB: www.gsk-india.com
    TELEPHONE: (022) 2495 9415     FAX: (022) 2498 1526
    SECTOR: PHARMACEUTICALS     GROUP: M N C
    TR AGENT: Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
    AUDITOR: Price Waterhouse & Co.
CHM: D. S. Parekh COMP SEC: A. A. Nadkarni (GM & Admin) YEAR OF INC: 1924 BSE CODE: 500660 FV (Rs): 10 DIV YIELD (%): 1.9

More pharmaceuticals Company Fact Sheets:   ALEMBIC PHARMAWYETH LTDSANOFI INDIABIOCON LTDVENUS REMEDIES


Today's Market

Strong Start to the Week; Cement Stocks Rally(Closing)

Share markets in India finished on a strong footing tracking positive trend in global markets after the market's favored candidate, Emmanuel Macron, won the first round of the French presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

Why Suddenly There is No Cash in ATMs(Vivek Kaul's Diary)

Apr 11, 2017

There have been a spate of media reports around ATMs not dispensing cash. What is really happening here?

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

Is PPF As An Investment Avenue Dead?(Outside View)

Apr 11, 2017

It's true, the interest on PPF has been lowered to 7.9%. PersonalFN evaluates if it's still a promising investment avenue.

More

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GSK PHARMA

GSK PHARMA - CADILA HEALTHCARE COMPARISON

Compare Company With Charts

COMPARE GSK PHARMA WITH

MARKET STATS